当前位置:
X-MOL 学术
›
Cytom. Part B Clin. Cytom.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparison of five diagnostic flow cytometry scores in patients with myelodysplastic syndromes: Diagnostic power and prognostic impact
Cytometry Part B: Clinical Cytometry ( IF 3.4 ) Pub Date : 2021-08-14 , DOI: 10.1002/cyto.b.22030 Uta Oelschlaegel 1 , Lorenz Oelschlaeger 1 , Malte von Bonin 2 , Michael Kramer 1 , Katja Sockel 1 , Brigitte Mohr 1 , Lisa Wagenfuehr 1 , Frank Kroschinsky 1 , Martin Bornhaeuser 3 , Uwe Platzbecker 4
Cytometry Part B: Clinical Cytometry ( IF 3.4 ) Pub Date : 2021-08-14 , DOI: 10.1002/cyto.b.22030 Uta Oelschlaegel 1 , Lorenz Oelschlaeger 1 , Malte von Bonin 2 , Michael Kramer 1 , Katja Sockel 1 , Brigitte Mohr 1 , Lisa Wagenfuehr 1 , Frank Kroschinsky 1 , Martin Bornhaeuser 3 , Uwe Platzbecker 4
Affiliation
Flow cytometry (FCM) is a co-criterion in myelodysplastic syndromes (MDS) diagnostics according to the WHO classification. The presented study compared diagnostic power and prognostic impact of different FCM-based scores.
中文翻译:
骨髓增生异常综合征患者五种诊断性流式细胞术评分的比较:诊断能力和预后影响
根据 WHO 分类,流式细胞术 (FCM) 是骨髓增生异常综合征 (MDS) 诊断的共同标准。本研究比较了不同基于 FCM 评分的诊断能力和预后影响。
更新日期:2021-08-14
中文翻译:
骨髓增生异常综合征患者五种诊断性流式细胞术评分的比较:诊断能力和预后影响
根据 WHO 分类,流式细胞术 (FCM) 是骨髓增生异常综合征 (MDS) 诊断的共同标准。本研究比较了不同基于 FCM 评分的诊断能力和预后影响。